A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Inclusion Criteria:

• Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1randomization

• Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).

• Must be willing to discontinue topical and/or systemic therapies for psoriasisbefore the first dose of study intervention.

• Must agree to avoid prolonged exposure to the sun and to refrain from the use oftanning booths, sun lamps, and other sources of ultraviolet light during the study

Exclusion Criteria:

• Have had a clinically significant flare of psoriasis during the 12 weeks before thebaseline, as assessed by the investigator.

• Have a history of erythrodermic psoriasis, generalized or localized pustularpsoriasis, predominantly guttate psoriasis, or medication-induced ormedication-exacerbated psoriasis.

• Have any known or suspected diagnosis of inflammatory conditions other thanpsoriasis and psoriatic arthritis, including but not limited to rheumatoidarthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemiclupus erythematosus.

• Have a diagnosis of psoriatic arthritis requiring, or are currently receiving,systemic immunosuppressant medical treatment (including corticosteroids,immunosuppressants, and biologics).

• Have a current or recent acute, active infection. Participant must have no symptomsor signs of confirmed or suspected infection and must have completed any appropriateanti-infective treatment for at least 30 days before screening and up torandomization/baseline.